Individualizing Treatment Options in Advanced ER-Positive Breast Cancer.

Slides:

Advertisements

Similar presentations

SABCS 2011 BOLERO-2 Updated Results

Advertisements

Robertson JFR et al. J Clin Oncol 2009;27(27):

Department of Surgery, United Christian Hospital Aromatase Inhibitors Current Use in Breast Cancer JHGR 16 Jan 2005 Dr. Sharon Chan Department of Surgery,

1Bachelot T et al. Proc SABCS 2010;Abstract S1-6.

These slides are intended to educate the scientific and medical community and keep them fully informed about continuing progress, as is their right, stipulated.

A Comparison of Fulvestrant 500 mg with Anastrozole as First-line Treatment for Advanced Breast Cancer: Follow-up Analysis from the FIRST Study Robertson.

Heterogeneity in hormone receptor positive breast cancer

ESMO 2011 Breast Cancer BOLERO-2 Authors: CARE Faculty (Drs. Anil Joy and Sunil Verma) Date posted: October 12, 2011.

Targeting endocrine-resistance pathways in breast cancer

© MediPaper 2016 ASCO 2016 Palbociclib (Ibrance™) Data MediPaper Study / AbstractPhIndicationLineNN BiomarkerMethodologyArms1 o EPORRCBRDCRmPF S (Mo) PFS.

Her-2 negative MBC 10/25/2016.

Cyclin Kinases inhibitors and beyond

CCO Independent Conference Coverage

CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data.

New Insights in the Hormone Therapy for Breast Cancer

PALOMA-2: Addition of Palbociclib to Frontline Letrozole Significantly Improves PFS in Postmenopausal ER+/HER2- Advanced Breast Cancer CCO Independent.

Neoadjuvant Palbociclib + Anastrozole in ER+/HER2- Breast Cancer

PHEREXA: Survival Data

CCO Independent Conference Coverage

Individualizing Treatment Options in Advanced ER-Positive Breast Cancer.

Endocrine Therapy for Metastatic Breast Cancer

Optimizing Combination Endocrine Therapy in HR-Positive Advanced Breast Cancer.

Presented By Luca Malorni at 2017 ASCO Annual Meeting

SAFETY AND EFFICACY OF EVEROLIMUS PLUS EXEMESTANE IN METASTATIC BREAST CANCER BEYOND THE SECOND LINE TREATMENT: A SINGLE INSTITUTION EXPERIENCE M. Giampaglia,

Endocrine Combinations in HR-Positive MBC: The Future Is Now

Evolving Paradigms in the Management of HR-Positive Breast Cancer

CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: Implementing Paradigms in Clinical Practice.

Volume 14, Issue 10, Pages (September 2013)

The Nurse View: Hormone Receptor-Positive Advanced Breast Cancer

Hormone Receptor Positive Metastatic Breast Cancer

Expanding Horizons in the Clinical Care of ER-Positive, HER2-Negative Metastatic Breast Cancer.

HR positive, Her-2 negative MBC

Treatment of Metastatic Breast Cancer

New Horizons in the Management of Advanced Breast Cancer

CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: A Clinical Update

Overall Program Goals. Overall Program Goals Current Approaches.

Program Goals. Targeting New Pathways for Overcoming Endocrine Resistance in Breast Cancer.

Navigating New Treatment Landscapes in HR-Positive, HER2-Negative Metastatic Breast Cancer.

Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer.

CDK4/6 Inhibitors in Breast Cancer:

CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data.

CDK4/6 Inhibitors in Practice

Managing gBRCA-Positive Metastatic Breast Cancer

Treating mRCC After Initial Antiangiogenic Therapy:

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.

Using CDK4/6 Inhibitors to Manage HR-Positive Metastatic Breast Cancer

Treatment of HR+ Breast Cancer: A Clinical Update

Hormone Receptor-Positive Advanced Breast Cancer:

Simona Borštnar, MD, PhD Division of Medical Oncology

Vincenzo Adamo Luminal Metastatic Breast Cancer:

Baselga J et al. SABCS 2009;Abstract 45.

Breast Cancer Statistics

CDK4/6 Biomarkers: Issues and Opportunities

Locally Advanced Lung Cancer

Hormone Receptor-Positive Advanced Breast Cancer Introduction

Introduction Advanced Hormone Receptor-Positive Breast Cancer

ABSTRACT ABCSG 6a MA17-1 MA.17R NSABP B-33. Extended Adjuvant Therapy With Aromatase Inhibitor Among Postmenopausal Breast Cancer.

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.

New Paradigms in HR-Positive Advanced Breast Cancer

Optimizing Treatment in HR-Positive Breast Cancer: A Case-Based Discussion.

CDK 4/6 Inhibitors in Breast Cancer

YIR On Demand Breast Hope S Rugo, MD Professor of Medicine

Martin M et al. Proc SABCS 2012;Abstract S1-7.

CDK4/6 Biomarkers: Issues and Opportunities

Navigating New Treatment Landscapes in HR+ HER2-Negative Advanced Breast Cancer.

Optimizing Front-Line Endocrine Therapy in Metastatic Breast Cancer

CDK4/6 Inhibitors.

Real-World Evidence.

DISSECTING THE DECISION

Miquel Àngel Seguí Palmer ¿Ciclinas para todas?

Presentation transcript:

Individualizing Treatment Options in Advanced ER-Positive Breast Cancer

Introduction Advanced ER-Positive BC

Maximizing Time of Tumor Endocrine Sensitivity

Case Study 1

Interactivity Question 1

1st Line Endocrine Therapy in ABC: Choice of ET + /- CDK 4/6 inhibitor

FALCON: Anastrozole vs Fulvestrant in Hormone Receptor-Positive Advanced BC

FALCON Trial Results

FALCON PFS by Patient Subgroups

Case Study 2

Interactive Question 2

MONALEESA-2: Ribociclib Plus Letrozole vs Letrozole in Hormone Receptor-Positive Advanced BC

MONALEESA-2 Results

MONALEESA-2 Safety Profile

MONALEESA-2 Subgroup Analysis

PALOMA-2 Palbociclib Plus Letrozole vs Letrozole Alone

PALOMA-2 Results

PALOMA-2 AE Summary

Case Study 3

Case Study 1 continued

Interactive Question 3

PALOMA-3 Palbociclib Plus Fulvestrant in Premenopausal/Perimenopausal mBC

PALOMA-3 Results

PALOMA-3 Safety Results

PALOMA-3 and SoFEA ESR1 Mutations

ESR1 Mutations PALOMA-3 Results

BOLERO-2: Everolimus Plus Exemestane vs Placebo Plus Exemestane

BOLERO-2 Results

BOLERO-2 Most Common Grade 3/4 AEs

Conclusions/Key Takeaways